Allay’s ATX101 offers post-surgical pain relief in Phase IIB trial

Allay Therapeutics has reported data from a Phase IIB clinical trial of its lead investigational product, ATX101, for post-surgical pain relief.

The trial, involving 13 sites across Australia, Canada, and the UK, compared ATX101 to the standard of care, bupivacaine, an approved non-opioid analgesic that typically provides only one day of pain relief.